Yahoo Finance Insider Sale: Chief Medical Officer Thomas Tu Sells Shares of Inari Medical Inc (NARI)
On July 15, 2024, Thomas Tu, Chief Medical Officer of Inari Medical Inc (NASDAQ:NARI), sold 16,520 shares of the company, according to the SEC Filing. Following this transaction, the insider now owns 313,257 shares of Inari Medical Inc.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and restore healthy blood flow in the venous system.
Over the past year, the insider has sold a total of 66,897 shares and has not made any purchases. This recent transaction is part of a broader trend observed over the past year, where Inari Medical Inc has seen 32 insider sells and only 2 insider buys.
Shares of Inari Medical Inc were trading at $55.09 on the day of the transaction. The company has a market cap of approximately $3.37 billion.
The stock's valuation metrics, including the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are calculated based on historical trading multiples, adjustments for past performance, and future business expectations.
According to the GF Value, the intrinsic value of Inari Medical Inc is estimated at $99.63 per share, suggesting that the stock is currently undervalued with a price-to-GF-Value ratio of 0.55. This valuation indicates a "Possible Value Trap, Think Twice" status.
This insider sale could be of interest to investors monitoring insider behaviors and company valuation metrics to gauge potential investment opportunities or risks associated with Inari Medical Inc (NASDAQ:NARI).
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
